Rcra Waste No. U059
Rcra Waste No. U059 Brand names, Rcra Waste No. U059 Analogs
- Acetyladriamycin
- Anthracyline
- Antibiotics From Streptomyces Coeruleorubidus
- Cerubidin
- Cerubidine
- DM1
- Daunamycin
- Daunarubicinum
- Daunoblastin
- Daunomycin
- Daunomycin Hydrochloride
- Daunomycin, Hydrochloride
- Daunorrubicina
- Daunorubicin Hcl
- Daunorubicin Hydrochloride
- Daunorubicin, Hydrochloride
- Daunorubicine
- Daunorubicinum [Inn-Latin]
- Daunoxome
- Leukaemomycin C
- Ondena
- Rcra Waste No. U059
- Rp 13057 Hydrochloride
- Rubidomycin
- Rubidomycin Hydrochloride
- Rubomycin C
Rcra Waste No. U059 Brand Names Mixture
- No information avaliable
Rcra Waste No. U059 Chemical_Formula
C27H29NO10
Rcra Waste No. U059 RX_link
http://www.rxlist.com/cgi/generic2/daunorubicin.htm
Rcra Waste No. U059 fda sheet
Rcra Waste No. U059 msds (material safety sheet)
Rcra Waste No. U059 Synthesis Reference
J. P. Parsh et al. J. Pharm. Sci. 56, 1691 (1967);
Rcra Waste No. U059 Molecular Weight
527.52 g/mol
Rcra Waste No. U059 Melting Point
208-209 oC
Rcra Waste No. U059 H2O Solubility
39.2 mg/L
Rcra Waste No. U059 State
Solid
Rcra Waste No. U059 LogP
0.766
Rcra Waste No. U059 Dosage Forms
Powder for solution; Suspension
Rcra Waste No. U059 Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Rcra Waste No. U059 Pharmacology
Daunorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Daunorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Daunorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.
Rcra Waste No. U059 Absorption
No information avaliable
Rcra Waste No. U059 side effects and Toxicity
LD50=20 mg/kg (mice, IV); LD50=13 mg/kg (rat, IV)
Rcra Waste No. U059 Patient Information
Rcra Waste No. U059 Organisms Affected
Humans and other mammals
